OCUGEN, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- OCUGEN, INC. payments for repurchase of common stock for fiscal 2021 was $0.00.
- OCUGEN, INC. payments for repurchase of common stock for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- OCUGEN, INC. payments for repurchase of common stock for fiscal 2019 was $48.00K.
- OCUGEN, INC. payments for repurchase of common stock for fiscal 2018 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-28 | |
| 2020-12-31 | $0.00 10-K · filed 2022-02-28 | |
| 2019-12-31 | $48.00K 10-K · filed 2022-02-28 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |